PSNL

$7.12

Post-MarketAs of Mar 17, 8:00 PM UTC

Personalis, Inc.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$7.12
Potential Upside
5%
Whystock Fair Value$7.48
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryDiagnostics & Research

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), ...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$744.98M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.11
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-35.02%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
6.46

Recent News

Motley Fool
Mar 2, 2026

Lightspeed Makes a Big Bet on Self-Driving Trucks, Loading Up on 7 Million Shares of Kodiak AI (KDK)

Specializing in AI-driven autonomy for commercial and defense vehicles, Kodiak AI targets clients seeking advanced navigation solutions.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Motley Fool
Mar 1, 2026

Lightspeed Management Made a Huge Bet on Navan (NAVN) With a Purchase of 49.9 Million Shares

Navan delivers AI-powered travel and expense management solutions for enterprise clients in the business software sector.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Moby
Feb 27, 2026

Personalis, Inc. Q4 2025 Earnings Call Summary

Moby summary of Personalis, Inc.'s Q4 2025 earnings call

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
MarketBeat
Feb 27, 2026

Personalis Q4 Earnings Call Highlights

Personalis (NASDAQ:PSNL) executives on the company’s fourth quarter 2025 earnings call highlighted accelerating clinical adoption of its ultra-sensitive NeXT Personal minimal residual disease (MRD) test, recent Medicare coverage wins in breast and lung cancer surveillance, and plans to scale test vo

BEARISH
Negative press. News cycle fixated on risk factors or misses.
GuruFocus.com
Feb 27, 2026

Personalis Inc (PSNL) Q4 2025 Earnings Call Highlights: Robust Clinical Growth Amidst Revenue ...

Personalis Inc (PSNL) reports significant clinical test growth and Medicare coverage wins, despite facing revenue and margin pressures.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.